PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children



Status:Recruiting
Conditions:Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:3 - 21
Updated:6/22/2018
Start Date:November 2012
End Date:November 2022
Contact:Sabine Mueller, MD
Email:cancertrials@ucsf.edu
Phone:877-827-3222

Use our guide to learn which trials are right for you!

This is an open label study of everolimus in children with recurrent or progressive low-grade
glioma.

This is an open label study of everolimus in children with recurrent or progressive low-grade
glioma. All patients will receive everolimus at a dose of 5 mg/m2/dose daily. An adaptive
Simon two-stage design for phase 2 studies of targeted therapies will be used to assess the
efficacy primary objective. The proposed treatment with everolimus will be deemed not worthy
of further investigation in this patient population if the true PFS at 6-months (PFS6) is
less than 50%. If in the first stage, with a combined sample size of 25, there is preliminary
evidence to suggest efficacy of everolimus is restricted to patients with PI3K/AKT/mTOR
activation as measured by p-S6 positivity, a total of 45 patients will be enrolled and the
design will have 81% statistical power to detect a true disease stabilization rate ≥70%. If
in the first stage there is preliminary evidence to suggest efficacy of everolimus is
independent of PI3K/AKT/mTOR activation, a total of 65 patients will be enrolled and the
design will have >95% statistical power to detect a true disease stabilization rate ≥70%.

Inclusion Criteria:

--Patients must have radiographic progressive or recurrent confirmed WHO grade I or II
astrocytomas, that was confirmed histologically at initial diagnosis. Progressive or
recurrent disease should be based on MRI according to the definition below.

Eligible histologies:

- Pilocytic Astrocytoma - 90600112

- Astrocytoma, Low Grade (Fibrillary astrocytoma, WHO Grade 2) - 10065886

- Astrocytoma, Low Grade (Low-grade Astrocytoma, NOS, WHO Grade 2) - 10003571

- Tissue from the initial diagnosis or recurrence must be made available for
correlative testing.

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least two dimensions on MRI.

- Patients may have had treatment (chemotherapy and/or radiotherapy) for any number
of relapses prior to this recurrence.

- Patients must have received their last dose of myelosuppressive anticancer
chemotherapy at least three (3) weeks prior to study registration or at least six
(6)weeks of nitrosourea.

- Patients must have received their last dose of other investigational or
biological agent > 7 days prior to study entry.

For agents that have known adverse events occurring beyond 7 days after administration,
this period should be extended beyond the time during which adverse events are known to
occur. This should be discussed with the study chair.

- If patients received prior monoclonal antibody treatment, at least three half-lives
must be elapsed by the time of treatment initiation. These patients should also be
discussed with the study chair.

- Patients must have received their last fraction of craniospinal or focal radiation to
primary tumor or other sites >12 weeks (3 months) prior to registration.

--Age ≥3 and ≤21 years.

- Because no dosing or adverse event data are currently available on the use of
everolimus in patients <3 years of age, these young children are excluded from this
study.

- Life expectancy of greater than 8 weeks.

- Patients must be able to swallow pills.

- Patient must have a Karnofsky (if ≥ 16 years of age) or Lansky Performance score
(if ≤ 16 years of age) of ≥50 by the time of registration.

- Patients must have adequate bone marrow function (ANC ≥ 1,000/mm3, platelet count
of ≥ 100,000/mm3, and hemoglobin ≥ 9 gm/dL) before starting therapy. Eligibility
level for hemoglobin may be reached by transfusion.

- INR ≤1.5. (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of
warfarin or on a stable dose of LMW heparin for >2 weeks at time of
randomization).

- Patients must have adequate liver function (SGPT/ALT ≤ 2.5 times ULN and
bilirubin ≤ 1.5 times ULN) before starting therapy.

- Patients must have adequate renal function (serum creatinine ≤ 1.5 times
institutional ULN for age or GFR ≥ 70 ml/min/1.73 m2) before starting therapy.

- Patients must have cholesterol level <350 mg/dL and triglycerides < 400 mg/dL
before starting therapy. In case one or both of these are exceeded, the patient
can only be included after initiation of appropriate lipid lowering medication
and documentation of cholesterol < 350mg/dL and triglycerides < 400mg/dl before
start of therapy.

- Patients must have normal pulmonary function testing for age based on pulse
oximetry.

- The effects of everolimus on the developing human fetus at the recommended
therapeutic dose are unknown. For this reason and because everolimus are known to
be teratogenic, women of child-bearing potential and men must agree to use
adequate contraception (hormonal or barrier method of birth control; abstinence)
prior to study entry and for the duration of study participation. Should a woman
become pregnant or suspect she is pregnant while participating in this study, she
should inform her treating physician immediately.

- Female patients of child bearing potential must not be breastfeeding or pregnant
as evidenced by a negative pregnancy test.

Exclusion Criteria:

- Patients with primary spinal cord tumors

- Patients receiving concomitant medication that may interfere with study outcome. For
example, patients cannot be on enzyme inducing anticonvulsants like phenytoin.

- Patients should not receive immunization with attenuated live vaccines within one week
of study entry or during study period. Close contact with those who have received
attenuated live vaccines should be avoided during treatment with everolimus. Examples
of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio,
BCG, yellow fever, varicella and TY21a typhoid vaccines

- Hepatitis B/C blood test must be done at screening for all patients. Patients who test
positive for Hepatitis C antibodies and the Hepatitis B antigen are ineligible.

- A known history of HIV seropositivity. HIV-positive patients on combination
antiretroviral therapy are ineligible because of the potential for pharmacokinetic
interactions with everolimus. In addition, these patients are at increased risk of
lethal infections when treated with marrow-suppressive therapy.

- Patients receiving chronic, systemic treatment with corticosteroids or another
immunosuppressive agent. Topical or inhaled corticosteroids are allowed.

- Patients may not have therapy for this recurrence (including radiation).

- Patients who do not have measurable disease on MRI.

- Patients who have been previously treated with an mTOR inhibitor.

- Patients with a known hypersensitivity to everolimus or other rapamycins (e.g.
sirolimus, temsirolimus).

- Patients receiving any other concurrent anticancer or investigational therapy.

- Patients with any clinically significant unrelated systemic illness that would
compromise the patient's ability to tolerate protocol therapy.

- Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of everolimus (e.g., ulcerative disease,
uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel
resection.

- Patients with inability to return for follow-up visits to assess toxicity to therapy.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Patients with a history of any other cancer (except non-melanoma skin cancer or
carcinoma in situ of the cervix), unless in complete remission and off of all therapy
for that disease for a minimum of 3 years.

Note: A detailed assessment of Hepatitis B/C medical history and risk factors must be done
at screening for all patients. HBV DNA and HCV RNA PCR testing are required at screening
for all patients with a positive medical history based on risk factors and/or confirmation
of prior HBV/HCV infection.
We found this trial at
18
sites
225 E Chicago Ave
Chicago, Illinois 60611
(312) 227-4000
Principal Investigator: Stewart Goldman, MD
Phone: 312-227-4873
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Kenneth Cohen, M.D.
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Principal Investigator: Jonathan Finlay, MD
Phone: 614-722-4087
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Sridharan Gururangan, FRCP
Phone: 352-294-8347
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Principal Investigator: Ghirish Dhall, MD
Phone: 323-361-8147
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
Principal Investigator: Tom B Davidson, MD
Phone: 310-825-6708
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Amar Gajjar, MD
Phone: 901-595-2615
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
Principal Investigator: Christopher Moertel, M.D.
Phone: 612-626-2778
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Jane Minturn, MD, PhD
Phone: 267-426-5026
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Kellie Nazemi, MD
Phone: 503-494-1543
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: Nicholas Whipple, MD,MPH
Phone: 801-662-4700
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Susan Chi, MD
Phone: 617-632-2291
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Oakland, California 94609
Principal Investigator: Joseph Torkildson, MD
Phone: 510-428-3272
?
mi
from
Oakland, CA
Click here to add this to my saved trials
1 Childrens Place
Saint Louis, Missouri 63110
Principal Investigator: Karen Gauvain, MD
Phone: 314-286-2790
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Diego, California 92123
Principal Investigator: John Crawford, MD,MS
Phone: 858-966-4930
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Sabine Mueller, MD
Phone: 877-827-3222
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Seattle, Washington 98195
Principal Investigator: Sarah Leary, MD
Phone: 206-667-7955
?
mi
from
Seattle, WA
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Principal Investigator: Lindsay Kilburn, MD
Phone: 202-476-3854
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials